Privacy Policy

 

 

GoodCap Pharmaceuticals Inc. Privacy Policy  

Last Updated July 13, 2022 

 

Privacy Policy Overview 

This Privacy Policy establishes rules to govern the collection, use and disclosure of personal information collected by GoodCap Pharmaceuticals Inc. (the “Company,”we) in the course of business, in compliance with federal and provincial privacy laws including the Personal Information Protection and Electronic Documents Act (Canada) and the Personal Information Protection Act (Alberta). 

This Privacy Policy applies to all individuals whose personal information the Company collects uses or discloses in the course of doing business. This includes individuals who are customers and all individuals who are contract workers, contractors, and consultants to the Company. It is our policy to only disclose your personal information as required or authorized by law or as otherwise set out in this policy. 

We reserve the right to change this policy from time to time as industry practice, the law, and our procedures in this area may change from time to time.  We will post the current version of this policy at www.goodcap.com/privacy 

 

What is Personal Information? 

For the purposes of this Privacy Policy, “personal information” means information about an identifiable individual, but does not include a person’s name, title, business address or telephone number, as an employee of an organization.  Where this Privacy Policy states that a list of items is “including”, the lists so described are meant to be examples and not exhaustive or exclusive.  

This Privacy Policy applies to all personal information that is collected, used or disclosed by the Company. The Company has designated a Privacy Officer to be accountable for the operation of this Privacy Policy. Individuals may question or report any privacy concerns, breaches, violations or compliance issues to the Privacy Officer at the address indicated below. 

If the policies and procedures outlined in this document do not address a specific situation, individuals are advised to contact the Privacy Officer privacy@goodcap.com for guidance or clarification. 

 

What Personal Information Do We Collect? 

The Company collects and uses only the personal information that we need for providing services and operating our business. Generally, the Company collects the following personal information from individuals for the various purposes set out below:  

  • Name, address, email address (work or personal)
  • Age, date of birth
  • Buying purposes
  • Credit card number

We normally collect information directly from our customers. We may collect your information from other persons with your consent or as authorized by law.  Before or at the time of collecting personal information, we identify the purposes for which we are collecting the information. We do not provide this notification when personal information is volunteered for an obvious purpose. If we wish to use or disclose your information for a new purpose not included in this policy, we will notify you and seek your consent. 

In addition, we also receive and send data from our servers and from your browser when you visit our website, including your IP address, the time and information about the page you requested and the website through which you were linked to our site, if any. We may use tracking technologies in a variety of ways, including the following: keeping count of return visits to our site; accumulating and reporting anonymous, aggregate (data collected in mass), statistical information on website usage; and determining which features users like best. The following are some of the tracking mechanisms we use: 

  • Cookies. To help us tailor our website, and the tools and applications on our Website, to the needs and interests of our users, we keep track of visitor interactions with our website through the use of cookies. Cookies are small text files stored on your browser when you visit a website or mobile applications. The “Help” function on most web browsers contains information on how to set your browser to disable cookies. However, if you do not accept cookies, you will not be able to take advantage of some features of our website. We use cookies to improve the user experience on our Website by making it more responsive to the needs of our users and to make it easier for us to recognize you when you return to our website. We also use cookies to analyze our website’s performance and to measure advertising performance. 

 

  • Web Beacons. To help us (and in some cases our advertisers and third-party service providers) keep track of how users are accessing particular pages or features within our website, and to track how users respond to ads and to other content we display on our Website, we may place a small file, called a web beacon, on some of our pages and on some of the listings and ads we distribute. We may also place a web beacon in the emails we send to you. When you open one of our emails or click on links within these emails, we track this click-through data to help us determine your interest in particular topics and measure the effectiveness of our communications to you.  

 

  • Web Analytics. We may collect, or have a third party collect on our behalf, data on how visitors use and navigate through our website, such as the number of users who visit various pages within our website, what they click on, whether they scroll up or down on particular pages, fill out forms, etc. We use this information to improve our website and learn about users, and may disclose it to our affiliates, or to third parties.in a summary form where no personal identifiers are included.  

 

  • Social Media. When you use one of the social media tools available on our website, we and the social media company operating the tool may collect information about you based on such use. The social media company’s use of that information will be subject to its own privacy policy. 

 

Using and Disclosing Personal Information

We will only use or disclose personal information where necessary to fulfill the purposes identified at the time of collection or for a purpose reasonably related to those purposes such as:  

  • To process transactions
  • To manage the Company’s business and operations, including customer relationships and investor matters
  • To meet legal and regulatory requirements
  • Informing individuals about the Company’s products and services that we believe may be of interest to them
  • To better understand an individual’s interests in our products and services and potential investment and to conduct market research
  • Deliver, develop, enhance or improve products and services
  • Evaluate suitability of candidates
  • Provide warranties for products and services
  • Provide information on future opportunities
  • Verify access rights to our website, account creation and purchases
  • To third party service providers to assist in the operation of our business and marketing
  • To our subsidiaries and affiliates
  • To enforce our legal relationship with you
  • As is necessary in contemplation of a business transaction


In the course of providing our services, we may share personal information with service providers who perform services on our behalf. These service providers help us operate our business, technology systems and applications, internal procedures, infrastructure and advertising and marketing. They provide services to us, such as fulfilling transactions, processing credit card payments, sending emails and postal mail, call centres, data hosting, contest administration, providing advertisements, and analytics services (e.g. tracking effectiveness of our marketing campaigns and analyzing usage of our website). We require these service providers to limit their access to and/or use of personal information to what is required to provide their services and require that those third parties adhere to confidentiality as well as security procedures and protections. Some of our service providers may be in the United States. When your personal information is used or stored in a jurisdiction outside of Canada, it may be subject to the law of this foreign jurisdiction, including any law permitting or requiring disclosure of the information to the government, government agencies, courts and law enforcement in that jurisdiction.
 
Company
 affiliates and subsidiaries may share personal information with each other and use it for the purposes described in this Privacy Policy. This allows Company and each entity within the group to comply with applicable laws, regulations and requirements and ensures that your information is consistent, accurate and up-to-date.  

We may disclose personal information to a third party in connection with a sale or transfer of business or assets, an amalgamation, reorganization or financing of parts of our business (including the proceedings of insolvency or bankruptcy). In the event the transaction is completed, your personal information will remain protected by applicable privacy laws. In the event the transaction is not completed, we will require the other party not to use or disclose your personal information in any manner whatsoever and to completely delete such information, in compliance with applicable laws.  

Applicable laws may permit or require the disclosure of personal information without consent in specific circumstances (e.g., when investigating and preventing suspected or actual illegal activities, including fraud, or to assist government and law enforcement agencies). These circumstances include situations when permitted or required by law or when necessary to protect our group of companies, our employees, our customers, or others. If this happens, we will not share more personal information than is reasonably required to fulfill that particular purpose.

 

Consent 

Ordinarily we ask for consent to collect, use or disclose personal information, except in specific circumstances where collection, use or disclosure without consent is authorized or required by law. We may assume your consent in cases where you volunteer information for an obvious purpose.   

You may withdraw consent to the use and disclosure of personal information at any time, unless the personal information is necessary for us to fulfil our reasonable business or legal obligations. We will respect your decision, but we may not be able to provide you with certain products and services if we do not have the necessary personal information. 

The purpose for collecting personal information is set out in this policy. Any necessary consents shall be obtained before personal information is collected, used or disclosed.   

We ask for your express consent for some purposes and may not be able to provide certain services if you are unwilling to provide consent to the collection, use or disclosure of certain personal information. Where express consent is needed, we will normally ask customers to provide their consent orally (in person, by telephone), in writing (by signing a consent form), or electronically (by clicking a button). 

In cases that do not involve sensitive personal information, we may rely on “opt-out” consent.  

The amount and type of personal information collected by the Company shall be limited to what is necessary to fulfill the identified purpose. Personal information shall only be used or disclosed for the purposes for which it is collected. Exceptions may be made with the consent of the individual or if authorized or required by law.  

You may always opt out from receiving marketing communications from us by contacting us as at info@goodcap.com. Even if you have opted out of receiving marketing communications from us, we may still contact you for transactional purposes, in compliance with applicable laws (e.g., for customer service). 

In certain cases, we may transfer your personal information outside of Canada, including to our service providers who may need to access, process or store your personal information in the United States. When your personal information is used or stored in a jurisdiction outside of Canada, it may be subject to the law of this foreign jurisdiction, including any law permitting or requiring disclosure of the information to the government, government agencies, courts and law enforcement in that jurisdiction.

 

How do I Access my Personal Information? 

Upon request received by the Company in writing, individuals shall be informed of the existence, use, and disclosure of their personal information records and shall be given access to that information. Requests to access personal information held by the Company should be directed to the Privacy Officer.   

Requests must be made in writing or by e-mail. Individuals may be required to verify their identity in order to access their personal information. Any such documentation provided shall be used for verification purposes only.  

The Company responds to requests for access to personal information within thirty (30) days of receipt of the request, or as may be permitted in accordance with applicable privacy legislation.  

A fee for reasonable costs incurred may be charged when responding to more complex requests. The individual will be informed of the applicable fee.  

Requested information will be provided in a form that is generally understandable.  

The Company will be as specific as possible when describing third parties to whom it has disclosed personal information about an individual. When it is not possible to provide a list of the organizations to which it has actually disclosed information, the Company will provide a list of organizations to which it is likely to have disclosed information.  

Individuals are permitted either to view the original record, or to request a copy, subject to limitations as permitted or required by law. To preserve the integrity of the record and ensure that documents are not removed from the Company, individuals wishing to view an original record will do so at the Company’s head office and under the supervision of designated the Company personnel.  

 

Limitations on Access 

The Company will only refuse access to information about you in those circumstances permitted or required by applicable privacy legislation.  

In the event that the Company refuses to provide access to information, it will provide you with the reasons for its refusal upon request. Exceptions may include information that contains references to or opinions of other individuals, information that cannot be disclosed for legal, security or commercial proprietary reasons, or information that is subject to solicitor-client or litigation privilege. The Company will respond to your requests for access in accordance with applicable privacy legislation.   

 

How will my Personal Information be Maintained? 

Personal information shall be kept as accurate, complete, and up-to-date as necessary for the purposes for which it is to be used.  

Individuals have the right to challenge the accuracy and completeness of the personal information that is maintained by the Company and have it amended as appropriate.  

Individuals seeking a correction or amendment to their personal information should direct their requests in writing to the Company’s Privacy Officer.   

All formal requests to amend personal information must be accompanied by appropriate supporting documentation. The Company’s Privacy Officer will manage any exceptions. The amended information will be transmitted to third parties, as appropriate.  

If the individual is not satisfied with the results of the request, the Company shall internally document the issue, and provide a response. The existence of the unresolved challenge will be transmitted to third parties, as appropriate.  

 

How is my Personal Information Stored and Secured? 

Personal information will be retained only as long as necessary and will be disposed of in a manner that is appropriate to the sensitivity of the information. We render customer personal information non-identifying, or destroy records containing personal information once the information is no longer needed. We use appropriate security measures when destroying customer personal information, including shredding paper records and permanently deleting electronic records. 

Personal information will be protected by security safeguards, appropriate to the sensitivity of the personal information.  

Please note that we use cloud-based services to store information in the following countries: Canada and the United StatesWhere personal information is stored or processed outside of Canada, it is subject to the laws of that foreign jurisdiction, and may be accessible to that jurisdiction’s governments, courts, law enforcement, or regulatory agencies.         

We will notify all required authorities including the Office of the Information and Privacy Commissioner of Alberta, without delay, of a security breach affecting personal information if it creates a real risk of significant harm to individuals. 

 

Questions 

Inquiries or complaints concerning compliance with this Privacy Policy should be addressed, in writing, to the Company’s Privacy Officer.  

Privacy Officer:  

22 Adelaide St. West, Suite 3400

Toronto, ON 

M5H 4E3

privacy@goodcap.com 

If you are not satisfied with the response from our Privacy Officer after making a complaint, you may have recourse to additional remedies under applicable privacy legislation. If the Privacy Officer is unable to resolve the concern, the customer or user may also write to the Office of the Information and Privacy Commissioner for Alberta or the Office of the Privacy Commissioner of Canada (as applicable). 

H.G.J.M. Vermetten PhD, MD

Clinical psychiatrist and Faculty member of the Department of Psychiatry at Leiden University in the Netherlands with 20+ years of experience working with veterans and other uniformed officers as Head of Research at the Military Mental Health Service with the Dutch Ministry of Defense and was affiliated with ARQ National Psychotrauma Center. He also has an Adjunct Professorship at the Department of Psychiatry of New York UMC.

Author of 300+ scientific papers and 40+ book chapters, plus additional book edits. Leading the landmark 10-year PRISMO study on military operations, he offered insights into PTSD. 

Trained in the Netherlands as well as in the USA in psychiatry and neuroscience (Stanford, Yale, and Emory University). He has a clinical as well as a research position with a focus on medical/biological as well as psychiatric aspects of complex psychotrauma in military as well as civilian populations. Renowned for pioneering work in novel drug developments, particularly MDMA, psilocybin, ketamine, and medical cannabis.

Lorne Gertner, BArch, ICD.D, MRIAC

Director

 

Serial entrepreneur at the lead of emerging industries

Co-founder of Cynapsus Therapeutics which was acquired for $841 million

Co-founded and is the former chairman of PharmaCan (later known as Cronos), which achieved a peak market capitalization of $7 billion

Co-founder of the Tokyo Smoke brand which is now owned by Canopy Growth after a purchase in 2018 for $542 million

Daniels Faculty of Architecture, Landscape, and Design at the University of Toronto

Portrait of Dr. Daryl Hudson

Darryl Hudson

Co-founder and Chief Innovation Officer

 

Deep expertise in molecular biology, neuroscience and genetics in psychedelics

Prior to founding GoodCap, Darryl co-founded InPlanta Biotechnology Inc. and Pathways Rx, where he led the development and commercialization of proprietary plant genetics

PhD in molecular biology and genetics from the University of Guelph

Ralph Landau

Chief Science Officer

 

30+ years executive leadership in pharmaceutical R&D, manufacturing and operations

Sandoz, Novartis, Merck, Elan, Fougera, Cambrex

Led the commercialization of over 50 products covering a number of dosage forms, including Veregen, the first ever botanical drug approved by the FDA

Ph.D., Chemical Engineering, from the University of Delaware

Bachelor of Science, Chemical Engineering, from the New Jersey Institute of Technology

Andrew Williams, MBA

Chief Financial Officer

 

17+ years in the Pharma/Biotech sector as a Chief Financial Officer with extensive start-up, strategic, financial and operational experience

Was the COO & CFO of Cynapsus Therapeutics, a specialty CNS pharmaceutical company that developed Kynmobi®, a sublingual thin film strip for the treatment of OFF episodes associated with Parkinson’s disease

In October 2016, Cynapsus was acquired for $841 million by Sunovion Pharmaceuticals

While serving as CFO, Cynapsus raised approximately $170 million via private and public offerings, including $90 million from the proceeds of a US Initial Public Offering and NASDAQ listing.

BAH Economics from Queen’s University and MBA from Ivey School of Business at Western University

Rochelle Stenzler, BSc Phm, ICD.D

Chair of Board

 

35+ years senior executive and board experience in Pharma/healthcare

Fmr. President/CEO Pharma Plus Drugmarts, Revlon Canada, TLC Laser Eye Centers and TouchLogic Corporation

Chair of Cynapsus Therapeutics which was acquired for $841million

Fmr. Director & Vice Chair of the Humber River Hospital

BScPhm, Pharmacy, University of Toronto

Theresa Matkovits, PhD

Director

 

20+ years experience as leader in global drug development and commercialization

Experience across multiple therapeutic areas including Endocrine Disorders, Anti-infectives, Antivirals, Central Nervous System Disorders (Schizophrenia, Bipolar Disorders, Generalized Anxiety Disorders, Major Depression, Migraine, Anesthesia), Women’s Health, as well as a number of orphan indications

Board Director in private and public-sector companies

Doctor of Philosophy (Ph.D.), Biochemistry and Molecular Biology, University of Medicine and Dentistry of New Jersey

Joseph Elliot, MSc, PhD

Director

 

More than 30 years as a serial entrepreneur and former venture capitalist

Broad experience pharmaceuticals, biologicals and vaccines in oncology and infectious diseases

Experienced in drug development, manufacturing, regulatory affairs (FDA, EMA, NICE, Health Canada, WHO and BfArM)

Held senior technical and international marketing positions with Pharmacia Canada Inc. (now Pfizer) and Connaught Laboratories Inc (now Sanofi-Pasteur Vaccines)

PhD in Medical Sciences from McMaster University

Carol Coughlin, MBA

Director, Chair of FAR Committee

 

20+ years experience as CFO specializing in healthcare

Experienced public company board leader, audit committee chair, and is highly skilled in corporate governance including board refreshment, strategic alternatives and M&A for growth and highly regulated companies

Loyola University in MD (MBA) and Towson University (BS Business), is a Board Leadership Fellow (NACD) and a Certified Public Accountant (active status)

Robert Dantzer, PhD, DVM

Professor in the Department of Symptom Research in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center, Houston, Texas

A pioneer in establishing the connection between depression and inflammation

Current research aims at understanding the role of inflammation and mitochondrial dysfunction in the pathophysiology of depression and fatigue

Authored more than 550 original research papers, reviews and book chapters on stress, anxiety, neuropeptides, brain-immune interactions, and inflammation-associated depression

Barbara Olasov Rothbaum, PhD, MD

Clinical researcher in Atlanta, USA with 37+ years of experience in medical practice, teaching, and research focused on Post-Traumatic Stress Disorder.

Author of 400+ scientific papers and chapters and served as Associate Editor of The Journal of Traumatic Stress.

Blue Ribbon Panel Member for Pentagon officials, consultant to the Department of Defense, and Member of the Institute of Medicine’s (IOM) Study on Assessment of Ongoing Efforts in the Treatment of PTSD

Professor of Psychiatry and Behavioral Sciences at the medical school of a high-ranking University in Atlanta, where she is a director of the Trauma and Anxiety Recovery Program and the Associate Vice Chair of Clinical Research.

Charles B. Nemeroff, PhD, MD

Chair and professor with the Department of Psychiatry and Behavioral Sciences at the University of Texas at Austin

Co-director of the Center for Psychedelic Research and Therapy

Directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences

Former Chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine

Laura Targownik, PhD, MD

Clinician Researcher in the Mount Sinai Hospital Inflammatory Bowel Disease Clinic. Director for the University of Toronto Division of Gastroenterology and Hepatology and a faculty member of the University of Toronto School of Public Health Institute for Health Policy, Management and Evaluation.

Founder of the Ontario Best Practices Research Initiative in IBD, Ontario’s premier source of real-world data and patient-reported data on IBD in Ontario. Authored or co-authored over 180 articles in peer-reviewed publications.

Current research focus on the costs and benefits of medications used in IBD, assessing how to optimize delivery of mental health care for persons with IBD in diverse practice settings.

Elizabeth Nielson, PhD

Co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for mood disorders, PTSD, and substance use problems. 

Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of psychedelic-assisted Psychotherapy and has served as a therapist on earlier FDA approved clinical trials of psilocybin-assisted treatments for treatment resistant depression. 

Assistant Professor of Clinical Medical Psychology in Psychiatry and Project Clinician at Columbia University where her research includes qualitative and mixed-methods projects to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy.

Ken Croitoru, PhD, MD

Professor of Medicine at the University of Toronto, where he is a member of the Institute of Medical Science and secondarily appointed to the Department of Immunology

Gastroenterologist and internist at Mount Sinai Hospital in Toronto, Canada with 35+ years of experience in medical practice, teaching, and research focused on gut inflammation

Worked extensively with the Crohn’s and Colitis Foundation of Canada where he helped to develop the IBD Research Institute, and is now a project leader of the GEM Project, a global clinical study coordinated out of the IBD research group at the Zane Cohen Centre at Mount Sinai Hospital

Cory Weissman, MD​

Head of Interventional Psychiatry at UC San Diego, focusing on the development of novel treatments, including psychedelic medicines, for patients with severe mental illness

Highly active in the field of psychedelic science, where he has published on psychedelic microdosing and led several studies investigating the potential use of psychedelics for suicidality

Former clinical and research fellow in brain stimulation at the University of Toronto 

Portrait of Steve Sadoff

Steven Sadoff

Co-founder and Chief Executive Officer

 

15+ years of leadership experience across highly regulated industries with 100+ innovative product launches

Proven track record of growing sales, building brands, and leading product-development teams for Bacardi, Labatt, Novartis, and Jamieson Laboratories